journal
https://read.qxmd.com/read/37733191/correction-to-birch-bark-extract-a-review-in-epidermolysis-bullosa
#1
Young-A Heo
No abstract text is available yet for this article.
September 21, 2023: Drugs
https://read.qxmd.com/read/37728865/vutrisiran-a-review-in-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis
#2
REVIEW
Tina Nie, Young-A Heo, Matt Shirley
Silencing the transthyretin (TTR) gene is an effective strategy in the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. Vutrisiran (Amvuttra® ), an RNA interference (RNAi) therapeutic targeting TTR mRNA, is approved in the USA and EU for the treatment of adults with polyneuropathy of hATTR amyloidosis. N-acetylgalactosamine conjugation and enhanced stabilisation chemistry are utilised to target vutrisiran to the liver and increase stability, respectively, allowing for subcutaneous administration once every 3 months...
September 20, 2023: Drugs
https://read.qxmd.com/read/37728864/alzheimer-s-disease-novel-targets-and-investigational-drugs-for-disease-modification
#3
REVIEW
Jeffrey L Cummings, Amanda M Leisgang Osse, Jefferson W Kinney
Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most of the target processes identified in the Common Alzheimer's Disease Research Ontology (CADRO) are represented by novel agents in trials. Inflammation and synaptic plasticity/neuroprotection are the CADRO categories with the largest number of novel candidate therapies. Within these categories, there are few overlapping targets among the test agents...
September 20, 2023: Drugs
https://read.qxmd.com/read/37725259/escalation-versus-induction-high-efficacy-treatment-strategies-for-relapsing-multiple-sclerosis-which-is-best-for-patients
#4
JOURNAL ARTICLE
Gilles Edan, Emmanuelle Le Page
After more than 2 decades of recommending an escalating strategy for the treatment of most patients with multiple sclerosis, there has recently been considerable interest in the use of high-efficacy therapies in the early stage of the disease. Early intervention with induction/high-efficacy disease-modifying therapy may have the best risk-benefit profile for patients with relapsing-remitting multiple sclerosis who are young and have active disease, numerous focal T2 lesions on spinal and brain magnetic resonance imaging, and no irreversible disability...
September 19, 2023: Drugs
https://read.qxmd.com/read/37695433/pharmacotherapy-for-dravet-syndrome-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials
#5
Simona Lattanzi, Eugen Trinka, Emilio Russo, Cinzia Del Giovane, Sara Matricardi, Stefano Meletti, Pasquale Striano, Payam Tabaee Damavandi, Mauro Silvestrini, Francesco Brigo
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong seizures. The management of seizures in DS has changed in recent years with the approval of new antiseizure medications (ASMs). OBJECTIVE: The aim of this study was to estimate the comparative efficacy and tolerability of the ASMs for the treatment of seizures associated with DS using a network meta-analysis (NMA). METHODS: Studies were identified by conducting a systematic search (week 4, January 2023) of the MEDLINE (accessed by PubMed), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and US National Institutes of Health Clinical Trials Registry ( https://www...
September 11, 2023: Drugs
https://read.qxmd.com/read/37665470/correction-to-remdesivir-a-review-in-covid-19
#6
Hannah A Blair
No abstract text is available yet for this article.
September 4, 2023: Drugs
https://read.qxmd.com/read/37658982/birch-bark-extract-a-review-in-epidermolysis-bullosa
#7
REVIEW
Young-A Heo
Birch bark extract (Filsuvez® ; also known as the developmental name Oleogel-S10), a topical gel consisting of 10% dry birch bark extract and 90% sunflower oil, is the first therapy approved in the EU and UK for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients aged ≥ 6 months old. In the pivotal double-blind, randomized, vehicle-controlled, phase III EASE trial in patients with EB, the primary endpoint was met, in which birch bark extract relative to control gel significantly increased the proportion of patients with first complete target wound closure within 45 days...
September 2, 2023: Drugs
https://read.qxmd.com/read/37656420/rozanolixizumab-first-approval
#8
REVIEW
Sheridan M Hoy
Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO® ) is a high affinity humanized immunoglobulin G4 monoclonal antibody directed against human neonatal Fc receptor (FcRn). Administered subcutaneously, it is being developed by UCB Pharma for the treatment of autoimmune diseases and received its first approval on 27 June 2023 in the USA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. Rozanolixizumab is the first agent to be approved in the USA for both anti-AChR and anti-MuSK antibody-positive gMG...
September 1, 2023: Drugs
https://read.qxmd.com/read/37639180/clinical-outcomes-with-glp-1-receptor-agonists-in-patients-with-heart-failure-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#9
Huilei Zhao, Yang Liu, Menglu Liu, Yi Xu, Qin Ling, Weichun Lin, Jing Zhang, Zhiwei Yan, Jianyong Ma, Weiguang Li, Yujie Zhao, Peng Yu, Xiao Liu, Jingfeng Wang
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, there remains uncertainty about the efficiency of GLP-1 RAs in patients with heart failure (HF). METHODS: Randomized placebo-controlled trials (RCTs) that reported the effect of GLP-1 RAs on prognosis in patients with HF were identified by searching databases. The primary outcome was defined as MACE...
August 28, 2023: Drugs
https://read.qxmd.com/read/37632671/pharmacological-management-of-orofacial-pain
#10
REVIEW
Marcela Romero-Reyes, Sherwin Arman, Antonia Teruel, Satish Kumar, James Hawkins, Simon Akerman
Orofacial pain is a category of complex disorders, including musculoskeletal, neuropathic and neurovascular disorders, that greatly affect the quality of life of the patient. These disorders are within the fields of dentistry and medicine and management can be challenging, requiring a referral to an orofacial pain specialist, essential for adequate evaluation, diagnosis, and care. Management is specific to the diagnosis and a treatment plan is developed with diverse pharmacological and non-pharmacological modalities...
August 26, 2023: Drugs
https://read.qxmd.com/read/37610614/pyoderma-gangrenosum-treatment-options
#11
REVIEW
Joachim Dissemond, Angelo V Marzano, Philip J Hampton, Alex G Ortega-Loayza
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients...
August 23, 2023: Drugs
https://read.qxmd.com/read/37597091/epcoritamab-first-approval
#12
REVIEW
James E Frampton
Epcoritamab (epcoritamab-bysp; Epkinly™; Tepkinly® ) is a subcutaneously administered CD3×CD20 T-cell-engaging bispecific antibody being co-developed by Genmab and AbbVie for the treatment of mature B-cell non-Hodgkin lymphoma subtypes (B-NHLs), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab received its first (conditional) approval on 19 May 2023, in the USA, for the treatment of adult patients with relapsed or refractory (R/R) DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥ 2 lines of systemic therapy...
August 19, 2023: Drugs
https://read.qxmd.com/read/37589788/remdesivir-a-review-in-covid-19
#13
REVIEW
Hannah A Blair
Remdesivir (Veklury® ), a nucleotide analogue prodrug with broad-spectrum antiviral activity, is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 infection. Unlike some antivirals, remdesivir has a low potential for drug-drug interactions. In the pivotal ACTT-1 trial in hospitalized patients with COVID-19, daily intravenous infusions of remdesivir significantly reduced time to recovery relative to placebo. Subsequent trials provided additional support for the efficacy of remdesivir in hospitalized patients with moderate or severe COVID-19, with a greater benefit seen in patients with minimal oxygen requirements at baseline...
August 17, 2023: Drugs
https://read.qxmd.com/read/37578592/insulin-tregopil-an-ultra-fast-oral-recombinant-human-insulin-analog-preclinical-and-clinical-development-in-diabetes-mellitus
#14
JOURNAL ARTICLE
Shashank Joshi, Vathsala Jayanth, Subramanian Loganathan, Vasan K Sambandamurthy, Sandeep N Athalye
Insulin therapy is indispensable for achieving glycemic control in all patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus. Insulin injections are associated with negative connotations in patients owing to administration discomfort and adverse effects such as hypoglycemia and weight gain. Insulin administered orally can overcome these limitations by providing a convenient and effective mode of delivery with a potentially lower risk of hypoglycemia. Oral insulin mimics the physiologic process of insulin secretion, absorption into the portal circulation, and subsequent peripheral delivery, unlike the subcutaneous route that results in peripheral hyperinsulinemia...
August 14, 2023: Drugs
https://read.qxmd.com/read/37566211/delandistrogene-moxeparvovec-first-approval
#15
REVIEW
Sheridan M Hoy
Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; ELEVIDYS® ) is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a gene encoding a micro-dystrophin protein [i.e. a shortened (138 kDa) version of the dystrophin protein expressed in normal muscle cells (427 kDa)] to all muscles involved in the pathology of Duchenne muscular dystrophy (DMD). Developed by Sarepta Therapeutics, it is the first gene therapy to be approved (in June 2023 under the Accelerated Approval pathway) for the treatment of DMD in the USA, where it is indicated for ambulatory paediatric patients aged 4 through 5 years with DMD and a confirmed mutation in the dystrophin (DMD) gene...
August 11, 2023: Drugs
https://read.qxmd.com/read/37556041/ritlecitinib-first-approval
#16
REVIEW
Hannah A Blair
Ritlecitinib (LITFULO™ ), an orally administered kinase inhibitor, is being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcerative colitis and Crohn's disease. On 23 June 2023, ritlecitinib received approval in the USA for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Ritlecitinib was approved in Japan on 26 June 2023 for the treatment of alopecia areata (limited to intractable cases involving widespread hair loss). Ritlecitinib has also received a positive opinion in the EU and is under regulatory review in the UK and China...
August 9, 2023: Drugs
https://read.qxmd.com/read/37540446/recent-advances-in-antiarrhythmic-drug-therapy
#17
JOURNAL ARTICLE
Arnela Saljic, Jordi Heijman, Dobromir Dobrev
Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regulatory and financial considerations, the number of novel antiarrhythmic targets and agents in the development pipeline has decreased substantially during the last few decades. However, several promising candidates remain and there are exciting developments in repurposing and reformulating already existing drugs for indications related to cardiac arrhythmias...
August 4, 2023: Drugs
https://read.qxmd.com/read/37535220/correction-to-concizumab-first-approval
#18
Susan J Keam
No abstract text is available yet for this article.
August 3, 2023: Drugs
https://read.qxmd.com/read/37505446/anti-tnf-agents-and-new-biological-agents-vedolizumab-and-ustekinumab-in-the-prevention-and-treatment-of-postoperative-recurrence-after-surgery-in-crohn-s-disease
#19
REVIEW
Javier P Gisbert, MarĂ­a Chaparro
Surgery for Crohn's disease (CD) is not curative, as postoperative recurrence (POR) after ileocolonic resection is the rule in the absence of prophylactic treatment. In the present article, we critically review available data on the role of anti-tumour necrosis factor (TNF) agents and new biologics (including vedolizumab and ustekinumab) in the prevention and treatment of POR after surgery in CD. Several studies (summarised in various meta-analyses) have confirmed the efficacy of anti-TNFs in the prevention of POR...
July 28, 2023: Drugs
https://read.qxmd.com/read/37436681/direct-acting-antivirals-and-the-risk-of-arrhythmias-and-conduction-disorders-in-patients-with-chronic-hepatitis-c-a-french-nationwide-cohort-study
#20
JOURNAL ARTICLE
Laurent Lam, Stanislas Pol, Ariel Cohen, Fabrice Carrat
OBJECTIVE: To quantify the risk of arrhythmias and conduction disorders (ACD) in patients receiving direct-acting antiviral (DAA) therapy for hepatitis C. DESIGN: All individuals aged 18 to 85 years old treated with DAAs between 01 January 2014 and 31 December 2021 were selected from the French national healthcare database (SNDS). Individuals with a history of ACD were excluded. The primary outcome was the incidence of hospitalization or medical procedure for ACD...
July 12, 2023: Drugs
journal
journal
26573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.